Clinical Trial Update: PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a DNA damage response inhibitor with or without anti-PD-L1 immunotherapy in patients with neoadjuvant-treatment-resistant resi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Breast Neoplasm, Triple Negative Breast Cancer (TNBC) | Phase 2 | Status: RECRUITING